Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea},

Barceló A., Piérola J., Esquinas C., de la Peña M., Arqué M., la Torre M.S., Alonso-Fernandez A., Barbé F.

Source: Eur Respir J 2012; 40: 1046-1048
Journal Issue: October

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Barceló A., Piérola J., Esquinas C., de la Peña M., Arqué M., la Torre M.S., Alonso-Fernandez A., Barbé F.. Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea},. Eur Respir J 2012; 40: 1046-1048

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Serum leptin levels in obstructive sleep apnoea patients
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


Elevated serum homocysteine levels in patients with obstructive sleep apnea syndrome
Source: Eur Respir J 2004; 24: Suppl. 48, 566s
Year: 2004

Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea
Year: 2007


Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2004 - Systemic and metabolic effects from OSA
Year: 2004


Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA
Year: 2012


Circulating survivin levels in patients with obstructive sleep apnea
Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers
Year: 2017

Plasma homocysteine (Hcy) levels in patients with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea
Year: 2007


Serum resistin level in pediatric obstructive sleep apnea
Source: Annual Congress 2008 - Paediatric respiratory epidemiology I: primary ciliary dyskinesia, sleep-disordered breathing, exercise-induced symptoms and rare diseases
Year: 2008

Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Year: 2010

Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 334s
Year: 2001

Investigation on serum adiponectin levels in patients with obstructive sleep apnea hypopnea syndrome
Source: Eur Respir J 2004; 24: Suppl. 48, 445s
Year: 2004

Serum fibrinogen in patients with obstructive sleep apnea
Source: Virtual Congress 2020 – Consequences for obstructive sleep apnoea and potential modalities for early identification
Year: 2020

Plasma orexin-A levels in patients with obstructive sleep apnea syndrome
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


Serum leptin levels in obese patients with severe obstructive sleep apnea syndrome
Source: Eur Respir J 2004; 24: Suppl. 48, 332s
Year: 2004

Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA)
Source: Eur Respir J 2006; 28: Suppl. 50, 573s
Year: 2006

Associations between increased serum leptin levels and the severity of obstructive sleep apnoea independent of obesity
Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing
Year: 2009


C-reactive protein (CRP) levels in obstructive sleep apnea (OSA) patients and relation to severity of OSA
Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea
Year: 2011


Does low plasma adiponectin level affect cardiovasculer risk in obstructive sleep apnea syndrome?
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea
Source: Eur Respir J 2008; 32: 1009-1015
Year: 2008



Relations between cystatin C plasma concentration and cardiovascular complications in patients with obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I
Year: 2012